The Lupus Research Alliance announced that in a public-private partnership with the U.S. Food and Drug Administration and the lupus patient community—as well as in collaboration with various government and medical agencies—they have launched the new Lupus Accelerating Breakthroughs Consortium to advance lupus trials and novel therapeutics. The new initiative will seek a multifaceted approach to eliminating the barriers to clinical breakthroughs in lupus research and patient care by utilizing diverse patient and researcher perspectives, improving efficacy assessment standards for lupus medications, and recognizing greater value in patient-reported outcomes. “The Lupus Accelerating Breakthroughs Consortium will … truly give [patients] who live with lupus and their caregivers a platform where they can be heard. [H]aving a voice in this process is immensely important … when designing clinical trials and measuring outcomes to develop tailored therapies in lupus,” concluded Veronica Vargas Lupo, MBA, Co-Leader of the Lupus Voices Council at the Lupus Accelerating Breakthroughs Consortium.
May 25, 2023